Hint mode is switched on Switch off
For swift navigation between sections

Ibio

PDF download

Choose all Reset all
Download Cancel
Organization name
Ibio Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

17/07/2026 Ibio: Shareholder Director Nominations, Other Events, Financial Statements And Exhibits
01/07/2026 Ibio: And In The Press Release Furnished As Exhibit 99.1 To This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Otherwise Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended And Shall Not Be Incorporated By Reference Into Any Filing With The U.s. Securities And Exchange Commission Made By The Company, Whether Made Before Or After The Date Hereof, Regardless Of Any General Incorporation Language In Such Filing. The Press Release Furnished As Exhibit 99.1 To This Current Report On Form 8k Includes “safe Harbor” Language Pursuant To The Private Securities Litigation Reform Act Of 1995, As Amended, Indicating That Certain Statements Contained Therein Are “forwardlooking” Rather Than Historical, Other Events, Financial Statements And Exhibits
07/05/2026 Ibio: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure, Financial Statements And Exhibits
08/04/2026 Ibio: Of The Current Report On Form 8k It Filed With The Securities And Exchange Commission On April 8, 2026 (the “original Form 8k”) To Correct A Typographical Error Contained Therein Regarding The Date That The Series G Warrants (the “series G Warrants”) To Purchase Up To 35,770,000 Shares Of The Company’s Common Stock, Par Value $0.001 Per Share (the “common Stock”) Will Expire. As Amended, This Amendment No. 1 Correctly States That The Series G Warrants Will Expire At 5:00 P.m. (new York City Time) On May 20, 2026. This Amendment No. 1 Also Updates The Number Of Outstanding Series G Warrants And Adds Disclosure Regarding The Number Of Outstanding Shares Of The Company’s Common Stock And The Issuance Of Prefunded Warrants Upon The Exercise Of Series G Warrants
23/02/2026 Ibio: Termination Of A Material Definitive Agreement, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001420720
  • EIN
    26-2797813
Registration is required to get access.